

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:48:53 ON 25 SEP 2011

=> file biosis medline caplus wpids uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'BIOSIS' ENTERED AT 15:49:38 ON 25 SEP 2011

Copyright (c) 2011 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:49:38 ON 25 SEP 2011

FILE 'CAPLUS' ENTERED AT 15:49:38 ON 25 SEP 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:49:38 ON 25 SEP 2011

COPYRIGHT (C) 2011 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 15:49:38 ON 25 SEP 2011

CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s label? (4a) target

L1 29662 LABEL? (4A) TARGET

=> s l1 and linker (4a) peptide (7a) bond

L2 144 L1 AND LINKER (4A) PEPTIDE (7A) BOND

=> s l2 and linker (4a) consecutive (4a) peptide bonds

L3 0 L2 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS

=> s l1 and linker (4a) consecutive (4a) peptide bonds

L4 0 L1 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS

=> s l2 and linker (4a) (amino acid or aliphatic chain or alkene or alkyne or ring or sugar)

3 FILES SEARCHED...

L5 88 L2 AND LINKER (4A) (AMINO ACID OR ALIPHATIC CHAIN OR ALKENE OR ALKYNE OR RING OR SUGAR)

=> s l5 and 2002/py

L6 4 L5 AND 2002/PY

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 4 DUP REM L6 (0 DUPLICATES REMOVED)

=> d l7 bib abs 1-4

L7 ANSWER 1 OF 4 USPATFULL on STN

AN 2002:272801 USPATFULL

TI Compositions and methods for the therapy and diagnosis of colon cancer

IN Stolk, John A., Bothell, WA, UNITED STATES

Xu, Jiangchun, Bellevue, WA, UNITED STATES

Chenault, Ruth A., Seattle, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20020150922 A1 20021017 <--
AI US 2001-998598 A1 20011116 (9)
PRAI US 2001-304037P 20010710 (60)
US 2001-279670P 20010328 (60)
US 2001-267011P 20010206 (60)
US 2000-252222P 20001120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 4 USPATFULL on STN
AN 2002:243051 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 20020132237 A1 20020919 <--
AI US 2001-867701 A1 20010529 (9)
PRAI US 2000-207484P 20000526 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN
AN 2002:242791 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES

Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Secrist, Heather, Seattle, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 20020131971 A1 20020919 <--
AI US 2001-33528 A1 20011226 (10)
RLI Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001,
PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,
SEATTLE, WA, 98104-7092
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN
AN 2002:148269 USPATFULL
TI Multivalent target binding protein
IN Leung, Shui-on, Shatin, HONG KONG
PI US 20020076406 A1 20020620 <--
AI US 2001-911610 A1 20010725 (9)
PRAI US 2000-220782P 20000725 (60)
DT Utility
FS APPLICATION
LREP FOLEY & LARDNER, Washington Harbour, Suite 500, 3000 K Street,
N.W.,
Washington, DC, 20007-5109
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1776

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A novel multivalent target binding protein which comprises a first and a second polypeptides and has at least three target binding sites is described. The first polypeptide of the multivalent target binding protein comprises a first scFv molecule and a first immunoglobulin-like domain which preferably comprises an immunoglobulin light chain variable region domain. The second polypeptide of the multivalent target binding protein comprises a second scFv molecule and a second immunoglobulin-like domain which preferably comprises an immunoglobulin heavy chain variable region domain. The first scFv molecule and the first immunoglobulin-like domain are preferably linked via a first extra amino acid sequence which preferably comprises an immunoglobulin light chain constant region domain. The second scFv molecule and the second immunoglobulin-like domain are preferably linked via a second extra

amino acid sequence which preferably comprises an immunoglobulin heavy chain constant region domain. The first and second extra amino acid sequences preferably associate with each other via at least one disulfide bond. The multivalent target binding protein of the present invention is useful for treating and detecting tumors and infectious lesions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 15 not 17
L8 84 L5 NOT L7

=> s 18 and 2002/pd
L9 0 L8 AND 2002/PD

=> d his

(FILE 'HOME' ENTERED AT 15:48:53 ON 25 SEP 2011)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 15:49:38 ON 25 SEP 2011

L1 29662 S LABEL? (4A) TARGET
L2 144 S L1 AND LINKER (4A) PEPTIDE (7A) BOND
L3 0 S L2 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS
L4 0 S L1 AND LINKER (4A) CONSECUTIVE (4A) PEPTIDE BONDS
L5 88 S L2 AND LINKER (4A) (AMINO ACID OR ALIPHATIC CHAIN OR ALKENE O
L6 4 S L5 AND 2002/PY
L7 4 DUP REM L6 (0 DUPLICATES REMOVED)
L8 84 S L5 NOT L7
L9 0 S L8 AND 2002/PD

=> s 18 and 2004/py
L10 4 L8 AND 2004/PY

=> d l10 bib abs 1-4

L10 ANSWER 1 OF 4 USPATFULL on STN
AN 2004:64489 USPATFULL
TI Templated molecules and methods for using such molecules
IN Pedersen, Henrik, Bagsvaerd, DENMARK
Gouilaev, Alex Haahr, Vesko Sjaelland, DENMARK
Franch, Thomas, Odense C, DENMARK
Sams, Christian Klarner, Frederiksberg C, DENMARK
Olsen, Eva Kampmann, Herlev, DENMARK
Slok, Frank Abilgaard, Kobenhavn N, DENMARK
Husemoen, Gitte Nystrup, Kobenhavn N, DENMARK
Felding, Jakob, Charlottenlund, DENMARK
Hyldtoft, Lene, Virum, DENMARK
Norregaard-Madsen, Mads, Birkerod, DENMARK
Godskesen, Michael Anders, Vedbaek, DENMARK
Glad, Sanne Schroder, Ballerup, DENMARK
Thisted, Thomas, Frederikssund, DENMARK
Freskgard, Per-Ola, Vellinge, SWEDEN
Holtmann, Anette, Ballerup, DENMARK
PA Nuevolution A/S, Copenhagen, DENMARK (non-U.S. corporation)
PI US 20040049008 A1 20040311 <--
US 7727713 B2 20100601
AI US 2002-175539 A1 20020620 (10)
PRAI DK 2001-962 20010620
US 2001-299443P 20010621 (60)

US 2002-364056P 20020315 (60)
DT Utility
FS APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300,
WASHINGTON, DC, 20001-5303
CLMN Number of Claims: 316
ECL Exemplary Claim: 1
DRWN 100 Drawing Page(s)
LN.CNT 11215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for synthesising templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 4 USPATFULL on STN
AN 2004:57417 USPATFULL
TI Javelinization of protein antigens to heat shock proteins
IN Rothman, James E., New York, NY, UNITED STATES
Hoe, Mee H., Irvington, NY, UNITED STATES
Mayhew, Mark, New York, NY, UNITED STATES
PI US 20040043419 A1 20040304 <--
AI US 2003-258147 A1 20030813 (10)
WO 2001-US12567 20010417
DT Utility
FS APPLICATION
LREP KENYON & KENYON, ONE BROADWAY, NEW YORK, NY, 10004
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to antigenic complexes, wherein an antigenic complex comprises a peptide or protein containing a plurality of epitopes non-covalently joined to a heat shock protein via a molecular tether referred to as a "javelin". Such complexes do not require that each epitope Be defined, and may in certain embodiments, elicit both antibody and cell-mediated immune reactions. The complexes of the invention may be used to induce therapeutic immune responses directed toward the treatment or prevention of infectious diseases and malignancies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 4 USPATFULL on STN
AN 2004:25211 USPATFULL
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
IN Roark, William Howard, Ann Arbor, MI, UNITED STATES
PI US 20040019053 A1 20040129 <--
AI US 2003-619662 A1 20030715 (10)
PRAI US 2002-396903P 20020717 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 8040

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 4 USPATFULL on STN

AN 2004:24365 USPATFULL

TI Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates

IN Pastan, Ira, Potomac, MD, UNITED STATES

Tsutsumi, Yasuo, Mino, JAPAN

Onda, Masanori, Rockville, MD, UNITED STATES

Nagata, Satoshi, Rockville, MD, UNITED STATES

Lee, Byungkook, Potomac, MD, UNITED STATES

Kreitman, Robert J., Potomac, MD, UNITED STATES

PI US 20040018203 A1 20040129 <--

AI US 2002-297337 A1 20021204 (10)

WO 2001-US18503 20010608

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 29

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 2142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the site-specific PEGylation of immunoconjugates. In particular, the present invention provides immunoconjugates wherein a connector molecule attaching a targeting molecule to an effector molecule is conjugated to one or more polyethylene glycol molecules. The present invention further provides methods for increasing the antitumor activity of an immunotoxin, comprising attaching in a site-specific manner one or more polyethylene glycol molecules to a linker connecting a toxic moiety to a targeting moiety of an immunotoxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 18 and label?/ti

L11 1 L8 AND LABEL?/TI

=> d 111 bib abs

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN

AN 2003:570953 CAPLUS

DN 139:113655

TI Fluorescent serine protease affinity labeling agents and methods for determining apoptotic state of cells

IN Phelps, David J.; Johnson, Gary L.; Lee, Brian W.; Darzynkiewicz, Zbigniew; Grabarek, Jerzy

PA Immunochemistry Technologies, LLC, USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2003059877	A2	20030724	WO 2002-US40920	20021219
	WO 2003059877	A3	20031211		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002367022	A1	20030730	AU 2002-367022	20021219
	US 20070269832	A1	20071122	US 2004-872754	20040621
PRAI	US 2001-342955P	P	20011221		
	WO 2002-US40920	W	20021219		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:113655

AB The invention provides novel serine protease affinity labels L-A-X-NHCH(R')C(:O)CH₂Cl (L = label; A = bond or linker; X = absent, amino acid, peptide; R' = H, (substituted)C₁-6-alkyl) or salts thereof, as well as compns. comprising such compds. or salts. The composition of the amino acid side-chain (R') along with the amino acid or amino acid sequence (peptide) of the X component of the affinity label affect the target selectivity of the labeled affinity ligand. Utilization of cell-permeable, enzyme-selective, labeled affinity ligands provides a precise mechanism for evaluating the current and future status of cell populations. Thus, the induction of proteinases in camptothecin-treated HL-60 cells was observed by fluorescence microscopy after addition of serine proteinase affinity inhibitors 5(6)-carboxyfluoresceinyl-L-phenylalanylchloromethyl ketone (FFCK) and 5(6)-carboxyfluoresceinyl-L-leucylchloromethyl ketone (FLCK) and caspase affinity inhibitor 5(6)-carboxyfluoresceinyl-L-valylalanylaspartylfluoromethyl ketone (FAM-VAD-FMK).

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 111 kwic

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN

TI Fluorescent serine protease affinity labeling agents and methods for

determining apoptotic state of cells

AB The invention provides novel serine protease affinity labels
L-A-X-NHCH(R')C(:O)CH₂Cl (L = label; A = bond or linker; X = absent,
amino acid, peptide; R' = H, (substituted)C₁-6-alkyl) or salts
thereof, as well as compns. comprising such compds. or salts. The composition
of the . . . acid side-chain (R') along with the amino acid or amino
acid sequence (peptide) of the X component of the affinity label affect
the target selectivity of the labeled affinity ligand. Utilization of
cell-permeable, enzyme-selective, labeled affinity ligands provides a
precise mechanism for evaluating the current and future status. . .

=>